ALLIANCEBERNSTEIN L.P. - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 82 filers reported holding ALLOGENE THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 1.3%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$458,756
-43.5%
144,718
-11.4%
0.00%
Q2 2023$811,840
+62.9%
163,348
+61.9%
0.00%
Q1 2023$498,486
-8.0%
100,908
+17.2%
0.00%
Q4 2022$541,619
-42.0%
86,108
-0.5%
0.00%
Q3 2022$934,000
-87.0%
86,519
-86.3%
0.00%
-100.0%
Q2 2022$7,176,000
+767.7%
629,507
+593.2%
0.00%
Q1 2022$827,000
-38.9%
90,808
+0.1%
0.00%
Q4 2021$1,353,000
-98.4%
90,708
-97.2%
0.00%
-100.0%
Q3 2021$82,684,000
+0.1%
3,217,285
+1.6%
0.03%0.0%
Q2 2021$82,586,000
-7.9%
3,166,630
+24.6%
0.03%
-15.4%
Q1 2021$89,717,000
+37.3%
2,541,559
-1.8%
0.04%
+25.8%
Q4 2020$65,343,000
-10.4%
2,588,858
+33.9%
0.03%
-20.5%
Q3 2020$72,937,000
+0.0%
1,934,145
+13.6%
0.04%
-9.3%
Q2 2020$72,928,000
+89.8%
1,703,120
-13.8%
0.04%
+53.6%
Q1 2020$38,428,000
-16.7%
1,976,724
+11.3%
0.03%
+7.7%
Q4 2019$46,148,000
+4.9%
1,776,303
+10.1%
0.03%
-3.7%
Q3 2019$43,982,000
+7.1%
1,613,709
+5.5%
0.03%
+3.8%
Q2 2019$41,071,000
+4.1%
1,529,649
+12.1%
0.03%0.0%
Q1 2019$39,462,000
+14.0%
1,365,007
+6.2%
0.03%0.0%
Q4 2018$34,617,0001,285,4270.03%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q4 2018
NameSharesValueWeighting ↓
VV Manager LLC 1,798,163$76,997,00067.53%
Wildcat Capital Management, LLC 1,515,524$64,895,00022.42%
TPG Group Holdings (SBS) Advisors, Inc. 19,716,306$844,252,00014.91%
REGENTS OF THE UNIVERSITY OF CALIFORNIA 1,279,281$54,779,0007.69%
Coastal Bridge Advisors, LLC 463,117$19,831,0006.33%
DSAM Partners (London) Ltd 235,098$10,067,0002.63%
Casdin Capital, LLC 625,000$26,763,0001.58%
Alpine Global Management, LLC 150,000$6,423,0001.13%
Perceptive Advisors 1,543,790$66,105,0001.07%
Avoro Capital Advisors LLC 1,128,594$48,326,0000.96%
View complete list of ALLOGENE THERAPEUTICS INC shareholders